There are numerous peptides reported of potential to target tumor-associated receptors, tissues or pathways (Raha et al., 2011), such as RGD targeting integrin (Ruoslahti and Pierschbacher, 1986), CDX-110 under developing by Celldex Therapeutics targeting EGFR (Del Vecchio and Wong, 2010), IPLVVPL targeting prostate cancer Hepsin (Kelly et al., 2008), and CREKA targeting tumor stroma (Simberg et al., 2007). This evidence concerns the gene EGFR and prostate cancer.